People: Hemispherx Biopharma Inc (HEB)

HEB on American Stock Exchange

0.20USD
24 May 2013
Price Change (% chg)

$0.00 (+2.19%)
Prev Close
$0.20
Open
$0.20
Day's High
$0.21
Day's Low
$0.20
Volume
364,355
Avg. Vol
529,065
52-wk High
$1.10
52-wk Low
$0.18

Search Stocks

Summary

Name Age Since Current Position

William Carter

 74 2006 Chairman of the Board, Chief Executive Officer, Chief Scientific Officer

Thomas Equels

 60 2010 Executive Vice Chairman of the Board, General Counsel, Secretary, Litigation Counsel

Charles Bernhardt

 51 2009 Chief Financial Officer, Chief Accounting Officer

Robert Dickey

 56 2009 Senior Vice President

Wayne Springate

 41 2011 Senior Vice President - Operations

Ralph Cavalli

 54 2010 Vice President - Quality Control

David Strayer

 66 2010 Chief Medical Officer, Medical Director - Regulatory Affairs

Richard Piani

 85 2005 Lead Independent Director

Iraj Kiani

 66 2002 Independent Director

William Mitchell

 77 1998 Independent Director

Dianne Will

 IR Contact
» Insider Trading

Biographies

Name Description

William Carter

 Dr. William A. Carter, M.D., is Chairman of the Board, Chief Executive Officer, Chief Scientific Officer of Hemispherx Biopharma Inc. He the co-inventor of Ampligen®, joined the company in 1978, and has served as: (a) Chief Scientific Officer since May 1989; (b) the Chairman of Board of Directors since January 1992; (c) Chief Executive Officer since July 1993; (d) President from April 1995 to November 2006; and (e) a Director since 1987. From 1987 to 1988, Dr. Carter served as Chairman. Dr. Carter was a innovator in the development of human interferon for a variety of treatment indications including various viral diseases and cancer. Dr. Carter received the first FDA approval to initiate clinical trials on a beta interferon product manufactured in the U.S. under his supervision. From 1985 to October 1988, Dr. Carter served as Chief Executive Officer and Chief Scientist. He received his M.D. degree from Duke University and underwent his post-doctoral training at the National Institutes of Health and Johns Hopkins University. Dr. Carter also served as Professor of Neoplastic Diseases at Hahnemann Medical University, a position he held from 1980 to 1998. Dr. Carter served as Professor and Director of Clinical Research for Hahnemann Medical University's Institute for Cancer and Blood Diseases, and as a member of the faculty at Johns Hopkins School of Medicine and the State University of New York at Buffalo. Dr. Carter is a Board certified physician and author of more than 200 scientific articles, including the editing of various textbooks on anti-viral and immune therapy.

Thomas Equels

 Mr. Thomas K. Equels is Executive Vice Chairman of the Board, General Counsel, Secretary, Litigation Counsel of Hemispherx Biopharma Inc. He has been a Director since 2008 and presently serves as Executive Vice Chairman, Secretary and General Counsel and Litigation Counsel. Mr. Equels is the President and Managing Director of the Equels Law Firm based in Miami Florida that focuses on litigation. For over a quarter century, Mr. Equels has represented national and state governments as well as companies in the banking, insurance, aviation, pharmaceutical and construction industries. Mr. Equels received his Juris Doctor degree with high honors from Florida State University. He is a summa cum laude graduate of Troy University and also obtained his Masters' Degree from Troy. He is a member of the Florida Bar Association and the American Bar Association.

Charles Bernhardt

 Mr. Charles T. Bernhardt, CPA, is Chief Financial Officer, Chief Accounting Officer of Hemispherx Biopharma Inc., since January 1, 2009. He is a Certified Public Accountant who has served as Chief Financial Officer and Chief Accounting Officer since January 1, 2009. He attained an undergraduate in Accountancy from Villanova University and received a Masters Degree in Business Administration from West Chester University of Pennsylvania. Mr. Bernhardt was formerly the Director of Accounting for Healthcare Division of Thomson Reuters, where he was responsible for their accounting operations including the Physicians’ Desk Reference business and shared financial services for the Healthcare and Scientific Divisions from 2006 to 2008. He was also the Regional Controller for Comcast Cable during 1999 to 2002, Director of Finance for TelAmerica Media from 2003 to 2006 and earlier in his career a member of the Internal Audit management teams for American Stores Corporation and ICI Americas/Zeneca (currently AstraZeneca Pharmaceuticals). In 1986, he became a C.P.A. licensed in Pennsylvania and New Jersey while with public accounting’s “Big Four” firm of KPMG.

Robert Dickey

 Mr. Robert Dickey, IV, is Senior Vice President of Hemispherx Biopharma Inc., since June 2009. He has approximately 15 years of previous experience in biotech management as a CFO, COO and CEO following a career as an investment banker. His experience spans startups to revenue stage companies involved in cancer and CNS drug development, transplantation and computational drug design. Mr. Dickey has specific experience in fund-raising, business development, project management, restructuring and international operations. Previously he spent 18 years as an investment banker, 14 of those at Lehman Brothers, with his background evenly split between M&A and capital markets transactions across a variety of industries. He has an undergraduate degree from Princeton University and an MBA from The Wharton School, University of Pennsylvania.

Wayne Springate

 Mr. Wayne S. Springate is Senior Vice President - Operations of Hemispherx Biopharma Inc. He was promoted to Senior Vice President of Operations on May 1, 2011. Mr. Springate joined Hemispherx in 2002 as Vice President of Business Development when Hemispherx acquired Alferon N Injection® and its New Brunswick, NJ manufacturing facilities. He led the consolidation of Rockville facility to New Brunswick location as well as coordinated the relocation of manufacturing polymers from South Africa to production facility in New Brunswick. He was also responsible for preparing and having a Preapproval Inspection by the FDA for New Brunswick manufacturing plant in connection with the filing of Ampligen® NDA. Currently he is managing a capital improvement budget to enhance Alferon® facility in accordance with cGMP. Previously, Mr. Springate served as President for World Fashion Concepts in New York and oversaw operations at several locations throughout the United States and overseas. Mr. Springate assists the CEO in details of operations on a daily basis and is involved in all aspects of manufacturing, warehouse management, distribution and logistics.

Ralph Cavalli

 Dr. Ralph Christopher Cavalli, Ph.D., is Vice President - Quality Control of Hemispherx Biopharma Inc., since April 15, 2010. Dr. Cavalli most recently served as Director of Quality Control at the Company’s New Brunswick, NJ manufacturing facility. He is currently responsible for manufacturing Alferon® Purified Drug Concentrate and active pharmaceutical ingredients for Ampligen® along with overseeing Quality Control (“QC”) Department to continue Laboratory Practices and Manufacturing Practices. Prior to joining Hemispherx, Dr. Cavalli served as Senior Director of Manufacturing Operations at Cytogen Corporation from 2006 until 2009, where he was responsible for the manufacture of Cytogen’s three commercial products. From 1999 until 2006, he initially worked at Discovery Laboratories as Associate Director of Analytical Services and then ultimately as Senior Director of Analytical and Technical Services, for which he was responsible for Quality Control and Process Development. Dr Cavalli received a Ph.D. in Chemistry from Temple University in Philadelphia, PA.

David Strayer

 Dr. David R. Strayer, M.D., is Chief Medical Officer, Medical Director - Regulatory Affairs of Hemispherx Biopharma Inc. He has acted as Medical Director since 1986. He has served as Professor of Medicine at the Medical College of Pennsylvania and Hahnemann University. Dr. Strayer is Board Certified in Medical Oncology and Internal Medicine with research interests in the fields of cancer and immune system disorders. He has served as principal investigator in studies funded by the Leukemia Society of America, the American Cancer Society, and the National Institutes of Health. Dr. Strayer attended the School of Medicine at the University of California at Los Angeles where he received his M.D. in 1972.

Richard Piani

 Mr. Richard C. Piani is Lead Independent Director of Hemispherx Biopharma Inc., since April, 2005. He has been a Director since 1995 and Lead director since April, 2005. Mr. Piani has been employed as a principal delegate for Industry to the City of Science and Industry, Paris, France, a billion dollar scientific and educational complex. Mr. Piani provided consulting to the company in 1993, with respect to general business strategies for European operations and markets. Mr. Piani served as Chairman of Industrielle du Batiment-Morin, a building materials corporation, from 1986 to 1993. Previously Mr. Piani was a Professor of International Strategy at Paris Dauphine University from 1984 to 1993. From 1979 to 1985, Mr. Piani served as Group Director in Charge of International and Commercial Affairs for Rhone-Poulenc and from 1973 to 1979 he was Chairman and Chief Executive Officer of Societe "La Cellophane", the French company which invented cellophane and several other worldwide products. Mr. Piani has a Law degree from Faculte de Droit, Paris Sorbonne and a Business Administration degree from Ecole des Hautes Etudes Commerciales, Paris.

Iraj Kiani

 Dr. Iraj Eqhbal Kiani, N.D., Ph.D., is Independent Director of Hemispherx Biopharma Inc., since May 1, 2002. Dr. Kiani is a citizen of the United States and England and resides in Newport Beach, California. Dr. Kiani served in various local government positions including the Mayor and Governor of Yasoug, Capital of Boyerahmand, Iran. In early 1980, Dr. Kiani moved to England, where he established and managed several trading companies over a period of some 20 years. Dr. Kiani is a planning and logistic specialist who is now applying his knowledge and experience to build a worldwide immunology network, which will use proprietary technology. Dr. Kiani received his Ph.D. degree from the University of Ferdosi in Iran, and his ND from American University.

William Mitchell

 Dr. William M. Mitchell, M.D., Ph.D., is Independent Director of Hemispherx Biopharma Inc., since July 1998. Dr. Mitchell is a Professor of Pathology at Vanderbilt University School of Medicine and is a board certified physician. Dr. Mitchell earned a M.D. from Vanderbilt and a Ph.D. from Johns Hopkins University, where he served as House Officer in Internal Medicine, followed by a Fellowship at its School of Medicine. Dr. Mitchell has published over 200 papers, reviews and abstracts that relate to viruses, anti-viral drugs, immune responses to HIV infection, and other biomedical topics. Dr. Mitchell has worked for and with many professional societies that have included the American Society of Investigative Pathology, the International Society for Antiviral Research, the American Society of Biochemistry and Molecular Biology and the American Society of Microbiology. Dr. Mitchell is a member of the American Medical Association. He has served on numerous government review committees, among them the National Institutes of Health, AIDS and Related Research Review Group. Dr. Mitchell previously served as one of Directors from 1987 to 1989.

Dianne Will

Basic Compensation

Name Fiscal Year Total

William Carter

 1,517,020

Thomas Equels

 838,274

Charles Bernhardt

 329,865

Robert Dickey

 310,297

Wayne Springate

 344,164

Ralph Cavalli

 244,002

David Strayer

 315,297

Richard Piani

 --

Iraj Kiani

 --

William Mitchell

 --

Dianne Will

 --
As Of 30 Dec 2011

Options Compensation

Name Options Value

William Carter

 5,773,919 359,794

Thomas Equels

 0 0

Charles Bernhardt

 0 0

Robert Dickey

 0 0

Wayne Springate

 0 0

Ralph Cavalli

 0 0

David Strayer

 150,000 11,200

Richard Piani

 0 0

Iraj Kiani

 0 0

William Mitchell

 0 0

Dianne Will

 0 0

Insider Trading

Name Shares Traded Price

CARTER WILLIAM A

 20,000 $0.00

CARTER WILLIAM A

 10,000 $0.00

CARTER WILLIAM A

 10,000 $0.00

KIANI IRAJ EQHBAL

 368,345 $0.26

STRAYER DAVID R

 44,900 $0.26

STRAYER DAVID R

 5,100 $0.26

KIANI IRAJ EQHBAL

 11,062 $2.26

KIANI IRAJ EQHBAL

 5,208 $2.40
» Full list on Insider Trading
Search Stocks